RU2012113844A - Пероральные суспензионные лекарственные формы ацетата эсликарбазепина - Google Patents

Пероральные суспензионные лекарственные формы ацетата эсликарбазепина Download PDF

Info

Publication number
RU2012113844A
RU2012113844A RU2012113844/15A RU2012113844A RU2012113844A RU 2012113844 A RU2012113844 A RU 2012113844A RU 2012113844/15 A RU2012113844/15 A RU 2012113844/15A RU 2012113844 A RU2012113844 A RU 2012113844A RU 2012113844 A RU2012113844 A RU 2012113844A
Authority
RU
Russia
Prior art keywords
dosage form
amount
agent
form according
sorbitol
Prior art date
Application number
RU2012113844/15A
Other languages
English (en)
Russian (ru)
Inventor
Теофилу Кардозу Ди ВАШКУНСЕЛУШ
ЛИМА Рикарду Жоржи Дуж САНТУШ
КОШТА Руй Сердейра Ди КАМПУШ
БАРРУКАШ Педру Мигел Да КОШТА
ПЕРЕЙРА Лижия София Ди КАШТРУ
Original Assignee
Биал-Портела Энд К.А., С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биал-Портела Энд К.А., С.А. filed Critical Биал-Портела Энд К.А., С.А.
Publication of RU2012113844A publication Critical patent/RU2012113844A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
RU2012113844/15A 2009-09-10 2010-09-10 Пероральные суспензионные лекарственные формы ацетата эсликарбазепина RU2012113844A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24119509P 2009-09-10 2009-09-10
US61/241,195 2009-09-10
PCT/PT2010/000038 WO2011031176A1 (en) 2009-09-10 2010-09-10 Oral suspension formulations of esclicarbazepine acetate

Publications (1)

Publication Number Publication Date
RU2012113844A true RU2012113844A (ru) 2013-10-20

Family

ID=43037794

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012113844/15A RU2012113844A (ru) 2009-09-10 2010-09-10 Пероральные суспензионные лекарственные формы ацетата эсликарбазепина

Country Status (13)

Country Link
US (2) US20130040939A1 (https=)
EP (1) EP2475357A1 (https=)
JP (1) JP2013504569A (https=)
KR (1) KR20120094473A (https=)
CN (1) CN102612359A (https=)
AR (1) AR078283A1 (https=)
AU (1) AU2010293105A1 (https=)
BR (1) BR112012005254A2 (https=)
CA (1) CA2773249A1 (https=)
IN (1) IN2012DN02379A (https=)
MX (1) MX2012002831A (https=)
RU (1) RU2012113844A (https=)
WO (1) WO2011031176A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
RU2012106827A (ru) 2009-07-27 2013-09-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Применение производных 5н-дибенз/в, f/азепин-5-карбоксамида для лечения фибромиалгии
WO2013032351A1 (en) 2011-08-26 2013-03-07 BIAL - PORTELA & Cª, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB201306095D0 (en) * 2013-04-04 2013-05-22 Bial Portela & Ca Sa New treatments
JP6122815B2 (ja) * 2014-02-20 2017-04-26 ライオン株式会社 経口製剤及びその製造方法
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
US11318145B2 (en) 2018-09-25 2022-05-03 Jubilant Generics Limited Eslicarbazepine suspension
WO2019058353A1 (en) * 2017-09-25 2019-03-28 Jubilant Generics Limited MODIFIED RELEASE SUSPENSION OF ESLICARBAZEPINE
WO2019058354A1 (en) * 2017-09-25 2019-03-28 Jubilant Generics Limited SUSPENSION OF ESLICARBAZÉPINE
US20220265552A1 (en) * 2017-09-25 2022-08-25 Jubilant Generics Limited Eslicarbazepine suspension
CN116440075B (zh) * 2023-06-01 2025-05-06 苏州中化药品工业有限公司 一种干混悬剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
EP1475091A1 (en) * 1993-10-01 2004-11-10 Roche Palo Alto LLC Mycophenolate mofetil - high dose oral suspensions
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
US6510799B2 (en) * 2001-07-02 2003-01-28 Magna Force, Inc. Apparatus, systems and methods for levitating and moving objects
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
CA2486553C (en) * 2002-06-17 2012-01-10 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7118508B2 (en) * 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
WO2006018814A2 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Oral liquid suspensions of metaxalone
EP2380575B1 (en) 2005-05-06 2015-02-25 Bial-Portela & CA, S.A. Eslicarbazepine acetate and use
US20060252745A1 (en) * 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007007182A2 (en) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Solid and liquid dosage forms of an antiepileptic agent

Also Published As

Publication number Publication date
AR078283A1 (es) 2011-10-26
JP2013504569A (ja) 2013-02-07
AU2010293105A8 (en) 2012-07-19
AU2010293105A1 (en) 2012-04-05
IN2012DN02379A (https=) 2015-08-21
WO2011031176A1 (en) 2011-03-17
CN102612359A (zh) 2012-07-25
EP2475357A1 (en) 2012-07-18
BR112012005254A2 (pt) 2016-03-15
KR20120094473A (ko) 2012-08-24
US20180256594A1 (en) 2018-09-13
CA2773249A1 (en) 2011-03-17
US20130040939A1 (en) 2013-02-14
MX2012002831A (es) 2012-05-08

Similar Documents

Publication Publication Date Title
RU2012113844A (ru) Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
WO2005117911A3 (en) Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
AU2003257588A1 (en) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
JO2852B1 (en) Anti-cancer compounds and pharmaceutical compositions
FI4374878T3 (fi) Karbetosiinia käsittävä farmaseuttinen koostumus
EA200400777A1 (ru) Фармацевтические композиции соединения платины
JP2014530801A5 (https=)
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
ATE544445T1 (de) Herstellung von sterilen wässrigen suspensionen mit mikronisierten kristallinen wirkstoffen zur inhalation
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
NO20082672L (no) Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
MX2025001734A (es) Formas farmacéuticas sólidas orales que contienen cannabinoides
WO2011016049A3 (en) A stable composition of ready-to-use gemcitabine injection
JP2018039810A5 (https=)
JP2016537364A5 (https=)
AU2002358819A1 (en) Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen
MX2025007158A (es) Inhibidores de gmp?amp sintasa ciclica y sus usos
WO2002009717A1 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient
EA200600377A1 (ru) Новая композиция
RU2005138127A (ru) Фармацевтические препараты, содержащие амоксициллин и клавуланат
JP2013227300A (ja) 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性組成物
WO2008009589A3 (en) Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150327